Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

被引：0
|
作者：
Lu Si
Xiaoshi Zhang
Zhen Xu
Qiudi Jiang
Lilian Bu
Xuan Wang
Lili Mao
Weijiang Zhang
Nicole Richie
Jun Guo
机构：
[1] Peking University Cancer Hospital & Institute,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)
[2] Sun Yat-sen University Cancer Center,undefined
[3] Roche Product Development in Asia Pacific,undefined
[4] Roche R&D Center China Ltd.,undefined
[5] Roche Innovation Center New York,undefined
[6] Genentech,undefined
[7] Inc.,undefined
来源：
BMC Cancer | / 18卷
关键词：
-positive; Advanced melanoma; Vemurafenib; China; Asia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
    Si, Lu
    Zhang, Xiaoshi
    Xu, Zhen
    Jiang, Qiudi
    Bu, Lilian
    Wang, Xuan
    Mao, Lili
    Zhang, Weijiang
    Richie, Nicole
    Guo, Jun
    BMC CANCER, 2018, 18
  • [2] Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study
    Dummer, Reinhard
    Goldinger, Simone M.
    Turtschi, Christian P.
    Eggmann, Nina B.
    Michielin, Olivier
    Mitchell, Lada
    Veronese, Luisa
    Hilfiker, Paul Rene
    Felderer, Lea
    Rinderknecht, Jeannine D.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (03) : 611 - 621
  • [3] Cobimetinib Plus Vemurafenib: A Review in BRAFV600 Mutation-Positive Unresectable or Metastatic Melanoma
    Gillian M. Keating
    Drugs, 2016, 76 : 605 - 615
  • [4] Phase I/II study of vemurafenib in patients with unresectable or recurrent melanoma with BRAFV600 mutations
    Yamazaki, Naoya
    Kiyohara, Yoshio
    Sugaya, Naofumi
    Uhara, Hisashi
    JOURNAL OF DERMATOLOGY, 2015, 42 (07) : 661 - 666
  • [5] A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAFV600E mutation-positive metastatic melanoma
    J. F. Grippo
    W. Zhang
    D. Heinzmann
    K. H. Yang
    J. Wong
    A. K. Joe
    P. Munster
    N. Sarapa
    A. Daud
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 103 - 111
  • [6] BRAFV600 mutation levels predict response to vemurafenib in metastatic melanoma
    Lebbe, C.
    How-Kit, A.
    Battistella, M.
    Sadoux, A.
    Podgorniak, M. P.
    Sidina, I.
    Pages, C.
    Roux, J.
    Porcher, R.
    Tost, J.
    Mourah, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2014, 28 : 96 - 96
  • [7] Safety of vemurafenib in patients with BRAFV600 mutated metastatic melanoma: the Spanish experience
    A. M. Arance
    A. Berrocal
    J. A. Lopez-Martin
    L. de la Cruz-Merino
    V. Soriano
    S. Martín Algarra
    L. Alonso
    P. Cerezuela
    B. La Orden
    E. Espinosa
    Clinical and Translational Oncology, 2016, 18 : 1147 - 1157
  • [8] Absolute Bioavailability of Vemurafenib in Patients With BRAFV600 Mutation-Positive Malignancies
    Zhang, Weijiang
    Colburn, Dawn
    Simmons, Brian
    Papai, Zsuzsanna
    Bertran, Enric
    Schadt, Simone
    Husser, Christophe
    Forbes, Harper
    Roethlisberger, Dieter
    Hartung, Thomas
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (04): : 496 - 504
  • [9] Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
    Chapman, P. B.
    Robert, C.
    Larkin, J.
    Haanen, J. B.
    Ribas, A.
    Hogg, D.
    Hamid, O.
    Ascierto, P. A.
    Testori, A.
    Lorigan, P. C.
    Dummer, R.
    Sosman, J. A.
    Flaherty, K. T.
    Chang, I.
    Coleman, S.
    Caro, I.
    Hauschild, A.
    McArthur, G. A.
    ANNALS OF ONCOLOGY, 2017, 28 (10) : 2581 - 2587
  • [10] Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis
    Blank, Christian U.
    Larkin, James
    Arance, Ana M.
    Hauschild, Axel
    Queirolo, Paola
    Del Vecchio, Michele
    Ascierto, Paolo A.
    Krajsova, Ivana
    Schachter, Jacob
    Neyns, Bart
    Garbe, Claus
    Sileni, Vanna Chiarion
    Mandala, Mario
    Gogas, Helen
    Espinosa, Enrique
    Hospers, Geke A. P.
    Miller, Wilson H., Jr.
    Robson, Susan
    Makrutzki, Martina
    Antic, Vladan
    Brown, Michael P.
    EUROPEAN JOURNAL OF CANCER, 2017, 79 : 176 - 184
12345